SCHEMBL16084183

SCHEMBL16084183

Cc1ccnc2c1nc(N)n2C1CCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.43
ADORA2A P29274 3/20 0.43
ADORA1 P30542 3/20 0.43
ADORA2B P29275 2/20 0.43
PDE4B Q07343 4/20 0.37
AKT1 P31749 2/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 2/20 0.37
MEN1 O00255 1/20 0.37
S1PR2 O95136 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP11B2 P19099 1/20 0.36
PDE7A Q13946 2/20 0.36
PDE2A O00408 1/20 0.35
PDE5A O76074 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084472 0.82 ADORA2A (0.40) ADORA3ADORA2AADORA1ADORA2BPDE4B
SCHEMBL16084206 0.75 CDK9 (0.38) ADORA3ADORA2AADORA1ADORA2BMAPT
SCHEMBL16084474 0.73 PDE4B (0.52) ADORA3ADORA2AADORA1ADORA2BPDE4B
SCHEMBL14980109 0.73 NOS2 (0.39) ADORA3ADORA2AADORA1ADORA2BPDE4B
SCHEMBL16084475 0.70 KCNQ2 (0.36) ADORA2APDE4BMAPTMAPK1PDE7A
SCHEMBL16084171 0.70 CDK9 (0.48) ADORA3ADORA2AADORA1ADORA2BMAPT
SCHEMBL19276068 0.69 MAPT (0.35) PDE4BMAPTMAPK1GAAPDE7A
SCHEMBL5775573 0.69 PDE4B (0.54) PDE4BMAPTMAPK1MEN1S1PR2
SCHEMBL5778683 0.69 PDE4B (0.54) PDE4BMAPTMAPK1MEN1S1PR2
SCHEMBL5775620 0.69 PDE4B (0.54) PDE4BMAPTMAPK1MEN1S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 EP disclosed
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 EP disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 US disclosed
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2018-10-23 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106536-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KCNA7, KCNA2, KCNK17 ADORA3 601/4885ADORA2A 1224/4885ADORA1 903/4885
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ADORA3 601/4885ADORA2A 1224/4885ADORA1 903/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ADORA3 614/4885ADORA2A 1226/4885ADORA1 902/4885
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ADORA3 601/4885ADORA2A 1224/4885ADORA1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.